Can China's Small Nucleic Acid Sector Produce a Global Pharma Leader?
Ribo Life Science
Small Nucleic Acid Drug Developer
Among the various tracks in innovative drugs, small nucleic acids are in the fastest growth phase, undergoing an epic leap from technological validation to commercial explosion.
2025Global Oligonucleotide Field in 2024BD, Total acquisition transaction amount exceeds300hundred million USD, Novartis120Acquisition for Hundreds of Millions of USDAvidity，GSK, Roche and Eli Lilly have successively entered the market. The clinical pipeline exceeds annually30%at an accelerated pace of expansion,siRNAAnnual Sales Surpass for the First TimeASO。
Meanwhile, Chinese capabilities have also risen rapidly. Among the global small nucleic acid pipelines entering the clinical stage, nearly40%From China——This ratio is about to exceed that in ourADC, the proportion in the field of bispecific antibodies.2026In the first quarter of the year, the total value of overseas licensing deals for domestic small nucleic acid therapeutics has approached70hundred million USD.
From a technological trend perspective, small nucleic acid drugs are transitioning from being liver-specific to becoming systemic therapeutics.GalNAcLiver-targeting technologies have become highly mature, with the competitive focus rapidly shifting toward extrahepatic delivery.——Kidneys, heart, adipose tissue, brain, and muscle.
All signals point to the same conclusion——Small Nucleic Acids Are at the Tipping Point of Leaping from a Billion-Dollar Market to a Hundred-Billion-Dollar Market: In This Historic Opportunity, Can Chinese Innovative Drugs Produce World-Class Enterprises?
The monoclonal antibody era has propelled Roche and AbbVie to success,ADCThe times have propelled Daiichi Sankyo onto the global stage. Each wave of technological revolution has given rise to world-class enterprises, and the oligonucleotide sector, with its platform technology offering far greater scalability than traditional drug modalities, inherently possesses the genetic makeup to nurture platform-type giants. Currently, overseas pioneersAlnylam、Ionis、ArrowheadAlready taking shape as a major player, and among Chinese enterprises, Ribo Life Science stands out with its pioneering listing on the Hong Kong Stock Exchange and blockbusterBDCollaboration and systematic breakthroughs in extrahepatic delivery platforms are opening up vast upside potential. Ribo Life Science has already established capabilities in the cardiovascular and metabolic fields comparable to those ofMNCWith global development experience and capabilities at the same level, the next step is to participate in the global competition in extrahepatic delivery technology.
The Peak Opportunity for Small Nucleic Acids Has Arrived: Seizing This Historic Moment Depends on Whether Chinese Enterprises Can Simultaneously Achieve Breakthroughs in Technology, Capital, and Commercialization.
The answer may be revealed within three to five years.
01
First-Mover Advantage+InternationalBDCertification
2025The year marks a watershed moment for the commercial realization of the small nucleic acid industry.
Global Blockbuster-Level Small Nucleic Acid Marketed Drugs from1individual became3piece,siRNAThe drug's sales surpassed for the first timeASO, completing the handover between two generations of technology.
Benefiting from the strong platform characteristics and chemical synthesis attributes of oligonucleotide R&D, Chinese pharmaceutical companies have leveraged their advantages in chemical synthesis and the engineer dividend to catch up and surpass competitors in the oligonucleotide sector.
The current competitive landscape in China is characterized by a hundred schools of thought contending. StartupsBiotechBowang, Jingyin, Shengyin, Sino-American Ruikang, Shi’an Biologics, and others each possess unique expertise; traditional pharmaceutical giants such as CSPC, Hengrui, and China Biologic Pharmaceuticals are also accelerating their market entry.
2026Year1In May, Ribo Life Science listed on the Hong Kong Stock Exchange, raising funds21HK$100 million. This is not only a corporate milestone but also a significant industry signal: China’s oligonucleotide sector, represented by Ribo Life Science, has rapidly entered the capitalization phase.
thanIPOMore compelling is the internationalBDrecognition.2026Year2Month, Ribo and GlobalMASHThe GodfatherMadrigalReaching a collaboration, with a total transaction value of up to44$100 million, down payment6000ten thousand US dollars.MadrigalWho is it?Madrigalis the world's first to possessMASHMarketed Drugs (Rezdiffra) company, chose Ribo Life Science and signed a contract in one go6FundsiRNAtherapy, equivalent to providing the most authoritative international certification for Ribo Life Science’s liver-targeting platform.
This is not all. Ribo Life Science and Boehringer Ingelheim (BI) As early as2024achieved a total value exceeding at the beginning of the year20billion-dollar platform-level collaboration to jointly develop therapiesMASHinnovative oligonucleotide therapies. This collaboration marks the first outbound licensing deal for an oligonucleotide drug between a Chinese pharmaceutical company and an overseas pharmaceutical company, serving as a significant bellwether. This year5In [Month], both parties announced that the project had achieved its third key milestone, marking Ribo Life Science’ssiRNAThe translational application of this technology in the field of metabolic liver disease has taken a solid step forward.
When Chinese Innovative Drugs Go GlobalBDAs the industry universally faces the challenge of commercialization, Ribo Life Science has demonstrated its strength through a series of milestone achievements.
When two top global pharmaceutical companies lock onto the same small nucleic acid technology platform in the same therapeutic area through deep platform collaboration, Ribo Life ScienceMASHThe moat in this field has far exceeded the scope covered by the success of a single pipeline.
WhetherIPOFundraising Scale,BDWhether in terms of total transaction value or the caliber of its partners, Ribo Life Science has established an unshakable leading position in China’s small nucleic acid sector.According to Patsnap data, in the field of small nucleic acids, Ribo Life Science's pipeline under development and the number of licensed intellectual property rights,all rank among the top three globally (Second only to Alnylam and Arrowhead), ranking first in China.Ribo Life Science is not only a pioneer in China’s oligonucleotide industry, but also a testament to the fact that China has caught up with the world’s top pharmaceutical companies in this field.
02
How to Outpace a Crowd of Red Ocean Competitors
GalNAcDelivery technology is currently the mainstream and preferred approach in the development of oligonucleotide drugs. For liver targets, the oligonucleotide drug landscape has shifted from initial land-grabbing to intense competition in a red ocean, with the low-hanging fruits of intrahepatic delivery nearly exhausted.
Based on the current pipeline distribution in China, cardiovascular and metabolic diseases and liver diseases remain the primary focus areas.PCSK9、APOC3、Lp(a)、AGT……Nearly all popular liver targets are crowded with a dense array of competitors.
Notably,AlnylamofGalNAcCore Delivery Structure Patents (e.g.L96Trident structure) expected2028Patents are set to expire, signaling that the patent barriers in the liver-targeted therapy field are about to loosen, while the window for latecomers to catch up is narrowing.
Therefore, in the intrahepatic therapeutic arena, the core competitive logic has shifted from who can develop a product to who can execute more intelligently in target selection, indication differentiation, and commercialization strategy.
Why Did Ribo Life Science Take the Lead in Breaking Through?
Across the industry, Ribo Life Science’s pipeline strategy clearly stands out: rather than engaging in cutthroat competition in a saturated market, it directly targets globally leading or most advanced therapeutic targets.
FXI（RBD4059/Vortosiran）：In anticoagulation, this super300billion-dollar market, RiboFXI siRNAFastest global progress. In the second quarter of this year, Ribo Life Science continuously supplied to EuropeEMASubmitted for stroke prevention in atrial fibrillation (SPAF) and venous thromboembolism (VTE) two ofIIbPhase clinical trial application. This is a saturation attack clinical strategy, aiming to establish multi-dimensional leading advantages in one track.VortosiranofIThe phase data is extremely robust, published in the internationally authoritative hematology journal “Blood Advances 》published data show: single-dose administrationFXIHighest Activity Inhibition91.6%, duration of drug efficacy169days, with no signs of bleeding. This is not merely a lead; it is defining the standard for the next generation of anticoagulant therapies.
APOC3（RBD5044）：As the second globally to enter clinical trialsAPOC3 siRNA, Ribo Life Science chose to target the blue ocean, not inFCSThis rare disease battlefield is not about close-quarters combat with giants, but rather a direct leap into hypertriglyceridemia, which affects a much larger patient population (HTG) field. EuropeIIPhase clinical trials are progressing smoothly this year1Month also obtained in ChinaNMPAofIIApproval Document,2launched rapidly in [Month], earlier thanArrowheadofPlozasiranGain a first-mover advantage in this indication.
PCSK9（RBD7022）：In this most fiercely contested therapeutic target area, Ribo Life Science has made its smartest strategic move by partnering with Qilu Pharmaceutical, a domestic commercialization giant. With Qilu Pharmaceutical’s advancement,RBD7022Becoming the first to enter RiboIIIlate-stage in-house pipeline. Rather than engaging in intense internal competition, it is better to let partners handle the competitive battles, while concentrating resources on more forward-looking innovative fronts.
Ribo Life Science’s product portfolio is not a mere collection ofme-toonot merely a collection of drugs, but a carefully designed combination therapy: usingPCSK9Remove the floor, useAPOC3Break the deadlock withFXIto lead the way, this strategic resolve in selecting major targets distinguishes it from many domesticBiotechThe key to widening the gap. Meanwhile, a large number of early-stage projects targeting other indications have been converted into a continuous stream of financial resources through external collaborations, thereby building a sustainable R&D ecosystem.
03
Next10The Decisive Move of the Year
The Upper Limit of Oligonucleotide Therapeutics Depends on the Boundaries of Delivery Technology.
For oligonucleotide therapeutics to become viable drugs, three major challenges must be overcome: first, avoiding degradation in the bloodstream; second, reaching the target tissue; and third, entering the target cells and escaping from endosomes to exert their therapeutic effects. Chemical modifications have addressed the first challenge, while the second and third rely entirely on delivery systems.
Over the past decade, intrahepatic delivery has spawned multiple blockbuster drugs. However, approximately human90%However, the pathogenic genes are expressed in extrahepatic tissues. A wide range of unmet clinical needs, including Alzheimer’s disease, heart failure, chronic kidney disease, and muscle building and weight loss, remain in the uncharted territory of nucleic acid therapeutics.
Targeted Delivery Beyond the Liver—Whether Targeting the Central Nervous System, Skeletal Muscle, Cardiac Muscle, Kidneys, or Adipocytes—Has Become the Next Multi-Billion-Dollar Blue Ocean Battlefield.
The difficulty in extrahepatic delivery stems from three major biological challenges: first, stringent tissue barriers—such as the blood-brain barrier, the glomerular filtration barrier, and low endocytic activity in cardiomyocytes—hinder drug access to target tissues; second, extremely low endosomal escape efficiency (less than1%), even if they enter cells, it is difficult for them to exert their therapeutic effects; third, poor cross-species stability leads to uncertainty in translating animal model data to humans.
It is precisely these high barriers that mean there is no absolute monopolist in global extrahepatic delivery; all players are essentially on a level playing field, and the window for overtaking on the curve has opened.
Currently, extrahepatic delivery has progressed from proof-of-concept to the phase of clinical realization.
Muscles:AvidityofAOC(Antibody-Drug Conjugate) pathway by Novartis120$100 million acquisition verification,Dynealso inDMDThe field submittedAOCMarketing Authorization Application for the Drug.
CNS：AlnylamDamnC16Lipophilic modification, administered via intrathecal injection, demonstrated excellent performance.
Fat:ArrowheadofTRiMPlatform, usingARO-ALK7Proven clinical efficacy in fat delivery, with remarkable fat-reduction results.
Kidneys:Judo BioDeveloped by the CompanySTRIKER™Platform, leveragingMegalinThe receptor willsiRNASpecifically delivered to the proximal tubular epithelial cells of the kidney, achieving70%knockdown of target genes.
However, these are mostly one-disease-one-drug targeted strategies, and have not yet formed a system likeGalNAcA standardized platform that can be easily reused.
This Year3Month, Ribo Life Science'sRiboPepSTAR™In EuropeRNA LeadersThe company made a stunning debut at the conference, unveiling its preclinical data in extrahepatic areas—including the kidneys, heart, and adipose tissue—all at once. Multiple core delivery metrics demonstrated competitiveness on par with leading international players.
AroundRiboPepSTAR™For extrahepatic delivery platforms, leveraging peptide-based and other diverse delivery modalities combined with precise screening and highly efficient chemical conjugation technologies, Ribo Life Science has achieved breakthroughs in the kidney, adipose tissue, heart,CNSSystematic technical validation has been completed in the four core areas.
Kidneys:Proximal renal tubule target gene inhibition rate reached80%, effective improvement in biomarkers was observed across various chronic kidney disease-related models, with the kidney-to-liver ratio exceeding hundreds of times. This means the "missile" detonates exclusively in the kidneys, causing almost no damage to the liver. Ribo Life Science's first kidney-targeted drug has enteredINDDeclaration Phase.
Heart:Only1mg/kgof low dose, achieving approximately in mouse cardiac target genes80%silence, while exhibiting minimal activity in the liver, kidneys, and muscles. This indicates a high degree of tissue selectivity, offering potential for future precision therapies for genetic heart diseases such as hypertrophic cardiomyopathy.
Fat:In non-human primates (NHP) in,9mg/kgFollowing a single dose, the inhibition rate of target genes in adipose tissue exceeds96%, duration of drug effect85days. This is not only a testament to the robust data, but also a promising outlook for future weight loss/MASHA technical reserve for combination therapy.
CNS：Through local administration, approximately90%inhibition. This provides a basis for Parkinson's, Alzheimer's, and otherCNSDisease-relatedRNAiTreatment has opened up new possibilities.
Unlike the common single-point breakthrough strategy adopted by global peers, Ribo Life Science does not merely address issues in a single organ; instead, it has established a platform-based extrahepatic delivery system capable of customized modifications for different organs. Currently, Ribo Life Science has built an extrahepatic delivery framework encompassing70The remaining patent portfolio submitted has established comprehensive barriers spanning from underlying structures to application scenarios. This platform-oriented technological mindset implies that the growth ceiling is determined not by the success or failure of individual projects, but by the scalability of the entire system.
This is not only a technological lead, but also means that Chinese oligonucleotide companies have the voice to define the industry standards for the next stage.
Conclusion
InclisiranThe sales miracle of a single injection every six months has validated the market penetration power of small nucleic acids in chronic disease management. Today, the entire industry is undergoing a more critical leap; whoever can first deliver robust data in new tissue battlegrounds such as the kidneys, heart, adipose tissue, and brain will become the price setter in the next cycle.
For China’s oligonucleotide industry, the most exciting aspect is not the current number of pipelines, but the fact that we are essentially on the same starting line as global players in terms of technology platforms, target selection, and capitalization pace.
Despite the current overall downturn in the innovative drug capital market, the positive trend for domestic small nucleic acid drugs remains unchanged. The recent share buyback announcement by Ribo Life Science is a testament to its confidence in long-term development. WithMNCMore than60hundred million U.S. dollarsBDRobust order books, global leadership in key targets and delivery platforms, and ample cash flow underpin a more solid commercialization pathway. These signals clearly demonstrate that Chinese small RNA therapeutics companies are not content with merely following; they aspire to define the global landscape.
For Chinese players that have secured a seat at the table, the next challenge is singular: in this most potent strategic window, whoever can first complete the transition from technology follower to global leader will become the next world-class enterprise.
Click "PharmaGo" below”, follow for more exciting content
Disclaimer
The WeChat Official Account push rules have been changed yet again. If you don't click“Seen”or not set to"Starred", we might just fade into the vast sea of literature~ Click here to make sure you don't miss the latest updates from Yaodu! ???